Sabby Management Lifted Holding in Gw Pharmaceuticals Plc (GWPH) as Shares Declined; Infosys LTD (INFY) Holder Forward Management Lifted Its Position by $1.45 Million

January 14, 2018 - By Michael Collier

Hal Mintz increased its stake in Gw Pharmaceuticals Plc (GWPH) by 81.48% based on its latest 2017Q3 regulatory filing with the SEC. Sabby Management Llc bought 12,803 shares as the company’s stock declined 18.00% while stock markets rallied. The hedge fund run by Hal Mintz held 28,517 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $2.89 million, up from 15,714 at the end of the previous reported quarter. Sabby Management Llc who had been investing in Gw Pharmaceuticals Plc for a number of months, seems to be bullish on the $3.66B market cap company. The stock decreased 0.42% or $0.56 during the last trading session, reaching $131.97. About 189,050 shares traded. GW Pharmaceuticals plc (NASDAQ:GWPH) has risen 31.90% since January 14, 2017 and is uptrending. It has outperformed by 15.20% the S&P500.

Forward Management Llc increased its stake in Infosys Ltd (INFY) by 49.9% based on its latest 2017Q3 regulatory filing with the SEC. Forward Management Llc bought 103,658 shares as the company’s stock rose 1.88% with the market. The institutional investor held 311,381 shares of the edp services company at the end of 2017Q3, valued at $4.54 million, up from 207,723 at the end of the previous reported quarter. Forward Management Llc who had been investing in Infosys Ltd for a number of months, seems to be bullish on the $36.05B market cap company. The stock decreased 2.66% or $0.46 during the last trading session, reaching $16.81. About 8.81M shares traded or 73.51% up from the average. Infosys Limited (NYSE:INFY) has declined 17.92% since January 14, 2017 and is downtrending. It has underperformed by 34.62% the S&P500.

Among 21 analysts covering Infosys (NYSE:INFY), 4 have Buy rating, 1 Sell and 16 Hold. Therefore 19% are positive. Infosys had 35 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of Infosys Limited (NYSE:INFY) has “Hold” rating given on Monday, August 21 by J.P. Morgan. The stock has “Neutral” rating by Nomura on Monday, July 18. The firm has “Hold” rating by Cowen & Co given on Friday, August 18. Robert W. Baird maintained it with “Hold” rating and $16.0 target in Friday, November 10 report. The rating was initiated by Sterne Agee CRT on Thursday, December 17 with “Neutral”. BMO Capital Markets maintained Infosys Limited (NYSE:INFY) rating on Friday, August 18. BMO Capital Markets has “Hold” rating and $16.0 target. The firm has “Neutral” rating by Susquehanna given on Monday, October 12. The rating was maintained by Stifel Nicolaus with “Hold” on Friday, August 18. The firm has “Buy” rating by Jefferies given on Wednesday, October 11. The firm has “Neutral” rating by Credit Suisse given on Monday, July 18.

Forward Management Llc, which manages about $5.17 billion and $893.11M US Long portfolio, decreased its stake in Avalonbay Cmntys Inc (NYSE:AVB) by 6,700 shares to 10,000 shares, valued at $1.78 million in 2017Q3, according to the filing. It also reduced its holding in Mobile Telesystems Pjsc (NYSE:MBT) by 39,500 shares in the quarter, leaving it with 53,500 shares, and cut its stake in Colony Northstar Inc.

Among 13 analysts covering GW Pharmaceuticals (NASDAQ:GWPH), 11 have Buy rating, 1 Sell and 1 Hold. Therefore 85% are positive. GW Pharmaceuticals had 24 analyst reports since August 13, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, December 4 by Cantor Fitzgerald. As per Friday, September 29, the company rating was maintained by Cantor Fitzgerald. Cantor Fitzgerald initiated GW Pharmaceuticals plc (NASDAQ:GWPH) rating on Friday, June 3. Cantor Fitzgerald has “Buy” rating and $181 target. The firm earned “Buy” rating on Thursday, December 28 by Leerink Swann. The stock of GW Pharmaceuticals plc (NASDAQ:GWPH) earned “Buy” rating by Piper Jaffray on Thursday, August 3. Evercore initiated the shares of GWPH in report on Wednesday, August 16 with “Buy” rating. On Thursday, December 14 the stock rating was upgraded by Goldman Sachs to “Buy”. The firm earned “Buy” rating on Thursday, October 26 by Cowen & Co. Roth Capital maintained GW Pharmaceuticals plc (NASDAQ:GWPH) rating on Monday, March 14. Roth Capital has “Buy” rating and $160 target. The firm has “Buy” rating by Cowen & Co given on Monday, September 25.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.